12 Month Price Forecast For KZR
Distance to KZR Price Forecasts
KZR Price Momentum
🤔 Considering Kezar Life Sciences (KZR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 2:48 PM UTC
KZR Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, KZR has a consensus that is neutral. The median price target is $14.50, with forecasts ranging from $11.00 to $18.00. Currently, there are 2 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
With KZR currently trading at $6.78, the median price forecast suggests a 113.9% upside. The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 165.5% upside, while Derek Archila at Wells Fargo provides the most conservative target, suggesting a 62.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KZR Analyst Consensus
KZR Price Target Range
Latest KZR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KZR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $0.00 |
| Nov 14, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $11.00 |
| Oct 18, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $0.00 |
| Oct 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $0.00 |
| Oct 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Downgrade | $0.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Jul 22, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| May 10, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Mar 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Dec 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Nov 27, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Nov 14, 2023 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $2.00 |
| Oct 12, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Oct 5, 2023 | JonesTrading | Catherine Novack | Hold | Downgrade | $0.00 |
| Sep 25, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $20.00 |
| Aug 11, 2023 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $0.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $18.00 |
| May 12, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $19.00 |
| May 12, 2023 | Wells Fargo | Derek Archila | Overweight | Maintains | $13.00 |
| Mar 16, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $21.00 |
Kezar Life Sciences Inc (KZR) Financial Data
Kezar Life Sciences Inc has a market capitalization of $50.27M with a P/E ratio of -0.5x. The company generates $7.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -1,422.0% and return on equity of -51.5%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Kezar Life Sciences Inc (KZR) Company Overview
About Kezar Life Sciences Inc
Develops novel therapeutics for immune diseases and cancer.
Kezar Life Sciences operates as a clinical-stage biotechnology company, focusing on the discovery and development of small molecule therapeutics. The company generates revenue through the advancement of its product candidates, particularly through clinical trials and potential commercialization of its therapies aimed at addressing unmet medical needs in immune-mediated diseases and cancer.
The company's lead candidate, zetomipzomib, is currently in Phase 2b trials targeting multiple indications, while its preclinical product KZR-261 aims to tackle tumors resistant to traditional treatments. Founded in 2015, Kezar Life Sciences is based in South San Francisco, California.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
58
CEO
Dr. Christopher J. Kirk Ph.D.
Country
United States
IPO Year
2017
Website
www.kezarlifesciences.comKezar Life Sciences Inc (KZR) Latest News & Analysis
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
1 month agoKezar Life Sciences (Nasdaq: KZR) reported Q3 2024 financial results and is nearing completion of the double-blind PORTOLA trial, with data expected in H1 2025.
Kezar Life Sciences' progress in the PORTOLA trial and upcoming data release could influence stock performance, signaling potential advancements in treatments for immune-mediated diseases.
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
1 month agoGlancy Prongay & Murray LLP is investigating Kezar Life Sciences (Nasdaq: KZR) for potential violations of state laws by the company and its executives. Investors may contact GPM for more information.
The investigation into Kezar Life Sciences for possible legal violations could lead to regulatory scrutiny, affecting stock performance and investor confidence.
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
1 month agoKezar Life Sciences, Inc. will execute a one-for-ten reverse stock split effective October 29, 2024, affecting its outstanding common stock shares.
Kezar Life Sciences' reverse stock split may impact share price and liquidity, reflecting attempts to meet listing requirements and attract institutional investors, influencing market perception and investment strategy.
What Makes Kezar Life Sciences (KZR) a New Buy Stock
1 month agoKezar Life Sciences (KZR) has been upgraded to Zacks Rank #2 (Buy), indicating improved earnings outlook, potentially leading to a stock price increase.
Kezar Life Sciences' upgrade to Zacks Rank #2 signals improved earnings expectations, potentially boosting investor confidence and driving the stock price up.
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
1 month agoKezar Life Sciences (Nasdaq: KZR) announced the IDMC approved the PORTOLA Phase 2a trial of zetomipzomib for AIH to proceed without modifications after reviewing safety data.
Kezar Life Sciences' positive trial update enhances investor confidence in its drug development progress, potentially increasing stock value and interest in the biotech sector.
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
1 month agoKezar Life Sciences' Board has unanimously rejected an unsolicited acquisition proposal from Concentra Biosciences for its common stock.
Kezar Life Sciences rejecting Concentra's acquisition proposal signals confidence in its value and potential, which may influence investor sentiment and stock performance.
Frequently Asked Questions About KZR Stock
What is Kezar Life Sciences Inc's (KZR) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Kezar Life Sciences Inc (KZR) has a median price target of $14.50. The highest price target is $18.00 and the lowest is $11.00.
Is KZR stock a good investment in 2025?
According to current analyst ratings, KZR has 2 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.78. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for KZR stock?
Wall Street analysts predict KZR stock could reach $14.50 in the next 12 months. This represents a 113.9% increase from the current price of $6.78. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kezar Life Sciences Inc's business model?
Kezar Life Sciences operates as a clinical-stage biotechnology company, focusing on the discovery and development of small molecule therapeutics. The company generates revenue through the advancement of its product candidates, particularly through clinical trials and potential commercialization of its therapies aimed at addressing unmet medical needs in immune-mediated diseases and cancer.
What is the highest forecasted price for KZR Kezar Life Sciences Inc?
The highest price target for KZR is $18.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 165.5% increase from the current price of $6.78.
What is the lowest forecasted price for KZR Kezar Life Sciences Inc?
The lowest price target for KZR is $11.00 from Derek Archila at Wells Fargo, which represents a 62.2% increase from the current price of $6.78.
What is the overall KZR consensus from analysts for Kezar Life Sciences Inc?
The overall analyst consensus for KZR is neutral. Out of 6 Wall Street analysts, 2 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $14.50.
How accurate are KZR stock price projections?
Stock price projections, including those for Kezar Life Sciences Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
